Document is current
Any future updates will be listed below
-
Authors
Navarre, Sophia
Ishibashi, Maki N.
Nair, Achuth
Reyes-Torres, Ivan
Belabed, Meriem
Halasz, Laszlo https://orcid.org/0000-0003-4726-7012
Park, Matthew D.
Mattiuz, Raphaël https://orcid.org/0000-0002-3292-1635
Ounadjela, Merouane
Gunset, Gertrude
Mansilla-Soto, Jorge https://orcid.org/0000-0003-2889-1397
Feucht, Judith
Cabriolu, Annalisa
Le Berichel, Jessica
Birbrair, Alexander
Eyquem, Justin https://orcid.org/0000-0001-8262-1190
Brown, Brian D. https://orcid.org/0000-0002-3670-8778
Merad, Miriam https://orcid.org/0000-0002-4481-7827
Sadelain, Michel https://orcid.org/0000-0002-9031-8025
Ahmed, Jalal https://orcid.org/0000-0002-1965-4069
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (DP5OD031828)
Lung Cancer Research Foundation
American Society of Clinical Oncology
- License Information
-
More Information
Article History
Received: 8 October 2025
Accepted: 8 April 2026
First Online: 22 May 2026
Competing interests
: M.M. serves on the scientific advisory board and hold stock from Compugen, Dynavax, Asher Bio, Dren Bio, Genenta, Oncoresponse, Myeloid Therapeutics, DemBio and Owkin. M.M. serves on the scientific advisory board of Innate Pharma and VirBio. M.M. receives funding for contracted research from Genentech, Regeneron and Boehringer Ingelheim. None of these relationships are directly related to the present work. M.S. reports research funding from Juno Therapeutics, Fate Therapeutics, Takeda Pharmaceuticals and Atara Biotherapeutics, unrelated to the present research. M.S. and J.E. are scientific cofounders of Mnemo Therapeutics, unrelated to the present research. M.S. serves on the scientific advisory board of St. Jude Children Research Hospital. All other authors declare no competing interests.
